Versartis gains on GHD results

Versartis Inc. (NASDAQ:VSAR) gained $2.16 (20%) to $13.14 after reporting 18-month data from a long-term extension study of somavaratan ( VRS-317), a long-acting recombinant human growth hormone (rhGH), in pre-pubertal children with growth hormone deficiency (GHD).

The extension study included 56 patients who received either twice-monthly 2.5 mg/kg or once-monthly 5 mg/kg doses of somavaratan for 12 months followed by twice-monthly 3.5 mg/kg doses for six months. The 3.5 mg/kg dose is currently being evaluated in the Phase III VELOCITY trial. ...